🟢 PFE is trading 2.5% up today after FDA expands IBRANCE breast cancer indication

PFE is trading 2.5% up at $24.27 after the FDA approved an expanded indication for its breast cancer drug, IBRANCE.

• The June 24, 2026, decision allows IBRANCE-based maintenance therapy for HR+, HER2+ metastatic breast cancer.
• IBRANCE is now the first CDK4/6 inhibitor approved for HR+ disease regardless of HER2 status, a milestone expected to support future revenue growth.